Sanyun Wu

Dr. Sanyun Wu


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 June 2020 in medRxiv
Verified
Preprint
Open access
PDF file
TLTao Liu
Tao Liu
SWSanyun Wu
Sanyun Wu
HTHuangheng Tao
Huangheng Tao
GZguang zeng
guang zeng
FZFuling Zhou
Fuling Zhou
XWXinghuan Wang
Xinghuan Wang
Background: It is to be determined whether people infected with SARS-CoV-2 will develop long-term immunity against SARS-CoV-2 and retain long-lasting protective antibodies after the infection is resolved. This study was to explore to explore the outcomes of IgG antibodies to SARS-CoV-2 in four groups of individuals in Wuhan, China. Methods: We included the following four groups of individuals who received both COVID-19 IgM/IgG tests and RT-PCR tests for SARS-CoV-2 from February 29, 2020 to April 29, 2020: 1470 hospitalized patients with COVID-19 from Leishenshan Hospital, Zhongnan Hospital of Wuhan University, and Wuhan No. 7 Hospital, 3832 healthcare providers without COVID-19 diagnosis, 19555 general workers, and 1616 other patients to be admitted to the hospital (N=26473). COVID-19 patients who received IgM/IgG tests <21 days after symptom onset were excluded. Results: IgG prevalence was 89.8% (95% CI 88.2-91.3%) in COVID-19 patients, 4.0% (95% CI 3.4-4.7%) in healthcare providers, 4.6 (95% CI 4.3-4.9 %) in general workers, and 1.0% in other patients (p all <0.001 for comparisons with COVID-19 patients). IgG prevalence increased significantly by age among healthcare workers and general workers. Prevalence of IgM antibodies to SARS-CoV-2 was 31.4% in COVID-19 patients, 1.5% in healthcare providers, 1.3% in general workers, and 0.2% in other patients. Conclusions: Very few healthcare providers had IgG antibodies to SARS-CoV-2, though a significant proportion of them had been infected with the virus. After SARS-CoV-2 infection, people are unlikely to produce long-lasting protective antibodies against this virus. Primary Funding Sources: Part of the study was supported by National Key Research and Development Program of China (2020YFC0845500). The content is solely the responsibility of the authors and does not necessarily represent the official views of the sponsors. Role of the Funder/Sponsor: The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript, and decision to submit the manuscript for publication. Data and code availability statement: Data and analyses codes are available from the corresponding authors on request. All request for raw and analyzed data and materials will be reviewed by the corresponding authors to verify whether the request is subject to any intellectual property or confidentiality obligations. Access will be granted after a signed data access agreement is attained.

13 September 2021 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
SWSanyun Wu
Sanyun Wu
PLPing Luo
Ping Luo
YYYalan Yu
Yalan Yu
BXBei Xiong
Bei Xiong
YWYingying Wang
Yingying Wang
XZXuelan Zuo
Xuelan Zuo

16 November 2023 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
SWSanyun Wu
Sanyun Wu
YLYixuan Li
Yixuan Li
RHRuiying Huang
Ruiying Huang
TLTing Li
Ting Li
YYYalan Yu
Yalan Yu
LHLi He
Li He

25 July 2021 in Archives of Medical Science
Verified
Journal Article
Open access
HXHui Xiao
Hui Xiao
JHJing He
Jing He
SWSanyun Wu
Sanyun Wu
HSHui Shen
Hui Shen
LLLi Liu
Li Liu
FZFuling Zhou
Fuling Zhou

22 December 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
GYGuangjiao Yin
Guangjiao Yin
YLYasu Lu
Yasu Lu
HPHuaqin Pan
Huaqin Pan
BDBin Deng
Bin Deng
SWSanyun Wu
Sanyun Wu
XYXujun Ye
Xujun Ye
Hemophagocytic lymphohistiocytosis (HLH) is an overwhelming immune system activation that manifests as hyperinflammation and life-threatening multiple organ failure. However, the clinical manifestations of the systemic inflammatory response in sepsis and fulminant cytokine storm caused by HLH macrophage activation are very similar and difficult to distinguish. HLH triggered by two novel gene defects manifesting with multiorgan dysfunction syndrome (MODS) and distributive shock has not been reported. A 14-year-old male patient was hospitalized with a high fever, his condition deteriorated rapidly, accompanied by cytopenia, shock, and MODS, and he was subsequently transferred to our intensive care unit (ICU) for symptomatic and organ-supportive treatments. Laboratory indicators of cytopenia, hypofibrinogenemia, hypertriglyceridemia, hyperferritinemia, high soluble CD25, low natural killer (NK) cell cytotoxicity, and hemophagocytosis in the bone marrow confirmed the diagnosis of HLH. Molecular genetic analysis revealed that two novel heterozygous gene mutations in AP3B1 (c.3197 C > T) and ATM (c.8077 G > T) might have accounted for the onset. After treatment, the patient’s condition successfully improved. This case report demonstrates the timely determination of underlying triggers and critical care supports (supportive and etiological treatment) of HLH related to the improved outcome.